U. Lancia, M.A. Russo, S. Marini - Vol. 10, September 2004, Issue 3
Testo Immagini Bibliografia Summary Indice
Clozapina nella schizofrenia resistente: una revisione
critica degli studi
Clozapine in treatment-resistant schizophrenia: a critical review
of data
1 Kaplan & Sadock. Comprehensive textbook of psychiatry, seventh edition. LWW, 2000.
2 Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
3 Linee guida per la farmacoterapia della schizophrenia della Società Italiana di Psicopatologia, Consensus Conference, Roma, 14-15 Aprile 2000. Giorn Ital Psicopatol 2000,6(Suppl).
4 Brenner HD, Dencker SJ, Goldstein MJ, Hubbard JW, Keegan DL, Kruger G, et al. Defining treatment refractoriness in schizophrenia. Schizophr Bull 1990;16:551-61.
5 American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia 1997.
6 American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia (Second Edition) (feb 2004).
7 Cassano GB, Pancheri P, eds. Trattato Italiano di Psichiatria. Milano: Masson 1999.
8 Davis KL, Charney D, Coyle JT, Nemeroff C. Neuropsychopharmacology: The Fifth Generation of Progress. LWW 2002.
9 Fitton A, Heel RC. Clozapine - A review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 1990;40:722-47.
10 Seeman P, Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 1999;156:876-84.
11 Wilkinson GR. Pharmacokinetics. In: Goodman LS & Gilman A, eds. The Pharmacological Basis of Therapeutics. Tenth Edition. McGraw-Hill 2001.
12 Chiodo LA, Bunney BS. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 1983;3:1607-19.
13 Hand TH, Hu XT, Wang RY. Differential effects of acute clozapine and haloperidol on the activity of ventral tegmental (A10) and nigrostriatal (A9) dopamine neurons. Brain Res 1987;415:257-69.
14 Stille G, Lauener H, Eichenberger E. The pharmacology of 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine (clozapine). Farmaco [Prat] 1971;26:603-25.
15 Costall B, Naylor RJ. Antagonism of the hyperactivity induced by dopamine applied intracerebrally to the nucleus accumbens septi by typical neuroleptics and by clozapine, sulpiride and thioridazine. Eur J Pharmacol 1976;35:161-8.
16 Deutch AY, Moghadamm B, Innis RB. Mechanisms of action of atypical antipsychotic drugs: implications for novel therapeutic strategies for schizophrenia. Schizophr Res 1991;4:121-56.
17 Owens MJ, Risch SC. Atypical antipsycotics. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Press Textbook of Psychopharmacology. Second Edition. Washington DC and London: American Psychiatric Press, Inc. 1998.
18 Moghaddam B. Preferential activation of cortical dopamine neurotransmission by clozapine: functional significance. J Clin Psychiatry 1994;55(Suppl B):27-9.
19 Youngren KD, Inglis FM, Pivirotto PJ, Jedema HP, Bradberry CW, GoldmanRakic PS, et al. Clozapine preferentially increases dopamine release in the Rhesus Monkey prefrontal cortex compared with the caudate nucleus. Neuropsychopharmachology 1999;20:403-12.
20 Qiao H, Noda Y, Nagai T, Furukawa H, Miura H, Kayukawa Y, et al. Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. NeuroReport 2001;12:11-15.
21 Lundberg T, Lindstrom L, Hartvig P, Reibring L, Agren H, Lundqvist H, et al. Serotonin-2 and dopamine-1 binding components of clozapine in frontal cortex and striatum in the human brain visualized by positron emission tomography. Psychiatry Res 1996;67:1-10.
22 Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156:286-93.
23 Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry 2001;158:360-9.
24 De Bartolomeis A. Potenziamento glutammatergico e glicinergico degli antipsicotici nella schizofrenia. Comunicazione Orale IX congresso SOPSI, 24-28 febbraio 2004 Roma. Itl J Psychopathol 2004;10:65-6.
25 Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994;36:717-25.
26 Lee MA, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry 1994;55(Suppl B):82-7.
27 Fujii DE, Ahmed I, Jokumsen M, Compton JM. The effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients. J Neuropsychiatry Clin Neurosci 1997;9:240-5.
28 Lee MA, Jayathilake K, Meltzer HY. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophr Res 1999;37:1-11.
29 Potkin SG, Fleming K, Jin Y, Gulasekaram B. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. J Clin Psychopharmacol 2001;21:479-83.
30 Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med 1997;337:809-15.
31 Rosenheck R, Lawson W, Crayton J, Cramer J, Xu W, Thomas J, et al. Predictors of differential response to clozapine and haloperidol. Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Biol Psychiatry 1998;44:475-82.
32 Rosenheck R, Dunn L, Peszke M, Cramer J, Xu W, Thomas J, et al. Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Am J Psychiatry 1999;156:88-93.
33 Rosenheck R, Chang S, Choe Y, Cramer J, Weichun X, Thomas J, et al. Medication continuation and compliance: a comparison of patients treated with clozapine and Haloperidol. J Clin Psychol 2000;5:382-6.
34 Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter T. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 1998;155:751-60.
35 Kane JM, Marder SR, Schooler NR, Wirshing WC, Umbricht D, Baker RW, et al. Clozapine and haloperidol in moderately refractory schizophrenia. A 6-month randomized and double blind comparison. Arch Gen Psychiatry 2001;58:965-72.
36 Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159:255-62.
37 Azorin JM, Spiegel R, Remington G, Vanelle JM, Péré JJ, Giguer M, et al. A double blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry 2001;158:1305-13.
38 Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, et al. on behalf of the risperidone study group. Risperidone versus clozapine in treatment resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry 1998;155:499-504.
39 Lindenmayer JP, Iskander A, Park M, Apergi FS, Czobor P, Smith R, et al. Clinical and neurocognitive effects of clozapine and risperidone in treatment refratory schizophrenic patients: a prospective study. J Clin Psychiatry 1998;59:521-7.
40 Breier AF, Malhotra AK, Tung-Ping S, Pinals DA, Elman I, Adler CM, et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psichiatry 1999;156:294-8.
41 Tollefson GD, Birkett MA, Kiesler GM, Wood AJ, and the Lilly resistant schizophrenia study group. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry 2001;49:52-63.
42 International Conference on Harmonisation Steering Committee. Note for Guidance on Statistical Principles in Clinical Trials. London, England: International Conference of Harmonization; March 1998. ICH Topic E9 (CPMP/ICH/363/96).
43 Fleischhacker WW, Czobor P, Hummer PM, Kemmler G, Kohnen R, Volavka J. Placebo or Active Control Trials of Antipsychotic Drugs? Arch Gen Psychiatry 2003;60:458-64.
44 Spivak B, Mester R, Wittemberg N, Maman Z, Weizman A. Reduction of aggressiveness and impulsiveness during clozapine treatment in chronic neuroleptic resistant schizophrenic patients. Clin Neuropharmachol 1997;20:442-6.
45 Meltzer HY, Anand R, Alphs L. Riduzione del rischio suicidario nella schizofrenia – Focus sul ruolo di clozapina. CNS Drugs 2000;15:355-65.
46 Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60:82-91.
47 Frankle W, Shera D, Berger-Hershkowitz H, Evins A, Connolly C, Goff D, et al. Clozapine-associated reduction in arrest rates of psychotic patients with criminal histories. Am J Psychiatry 2001;158:270-4.
48 Conley RR,Carpenter WT, Tamminga CA. Time to clozapine response in a standardized trial. Am J Psychiatry 1997;154:1243-7.
49 Van der Zwaag C, McGee M, McEvoy JP, Freudenreich O, Wilson WH, Cooper TB. Response of patients with tratment refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 1996;153:1579-84.
50 Llorca PM, Lancon C, Disdier B, Farisse J, Sapin C, Auquier P. Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentration. Rev Psych Neurosci 2002;27:30-7.
51 Simpson GM, Jossiassen RC, Stanilla JK, de Leon J, Nair C, Abraham G, et al. Double blind study of clozapine dose response in chronic schizophrenia. Am J Psychiatry 1999;156:1744-50.
52 Conley RR, Tamminga CA, Kelly DL, Richardson CM. Treatment resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biol Psychiatry 1999;46:73-7.
53 Wahlbeck K, Cheine M, Essali MA. Clozapine versus typical neuroleptic medication for schizophrenia (Cochrane Review). Oxford: The Cochrane Library, Issue 2, 2002.
54 Tuunainen A, Wahlbeck K, Gilbody SM. Newer atypical antipsychotic medication versus clozapine for schizophrenia (Cochrane Review). Oxford: The Cochrane Library, Issue 2, 2002.
55 Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second generation antipsychotics. Arch Gen Psychiatry 2003;60:553-64.
56 Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-6.
57 Lieberman JA, Alvir JM. A report of Clozapine-induced agranulocytosis in the United States. Drugs Safety 1992;7(Suppl 1):1-2.
58 Hagg S, Spigset O, Bate A, Hons BA, Soderstrom TG. Myocarditis related to clozapine treatment. J Clin Psychopharmacol 2001;21:382-8.
59 Scheda tecnica del prodotto Leponex®. Novartis Farma S.p.A., Marzo 2000.
60 Scheda tecnica del prodotto Clozaril®, riportata in Martindale: The Extra Pharmacopoeia, 1999.